ClinicalTrials.gg
Active, not recruitingNCT06848296VSA012-1002Updated May 4, 2026

Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria

A Phase 1 interventional study of VSA012 in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Bisirna Therapeutics Pte. Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Bisirna Therapeutics Pte. Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
18th of 47
50 · median 40
Started
2025
with 11 others
Phase 1
13 of 51
5 open now
Primary completion
2027-02
later than 14 of 28 live
Registered
29th of 51
by date

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 18th largest by enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2025, is one of 13 in phase 1, reaches primary completion later than 14 of the 28 other live ones, and was the 29th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

The complement system is an important component of the innate immune system. Abnormal activation, inadequate regulation and control of the complement system, as well as impaired and dysfunctional effector functions, underlie complement mediated diseases including PNH. VSA012 targeting complement system has the potential to treat a variety of diseases associated with abnormal activation of the complement system.The purpose of VSA012-1002 is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics and efficacy of VSA012 Injection in subjects with PNH.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion and Exclusion Criteria for Groups 1-4

  • Participants voluntarily participate in this clinical study, and voluntarily sign the ICF;
  • ≥ 18.0 kg/m2; male or female; 18 to 75 years of age;
  • Confirmed diagnosis of PNH by clinical manifestation and flow cytometry; granulocyte clone size ≥ 10%;
  • Presence of one or more of PNH-related signs or symptoms within 3 months prior to screening;
  • \< 100 g/L;
  • LDH value > 1.5 × ;
  • One of the following criteria for prior drug therapy for PNH must be met:

    1. Having never received any complement inhibitor therapy;
    2. Having received C5, C3, or CFB complement inhibitors and having discontinued the complement inhibitor for more than 5 half-lives or 3 months prior to screening;
  • Participants are willing to receive meningococcal vaccine and pneumococcal vaccine at least 14 days prior to dosing.

Inclusion and Exclusion Criteria for Groups 5

  • Participants voluntarily participate in this clinical study, and voluntarily sign the ICF;
  • BMI ≥ 18.0 kg/m2; male or female; 18 to 75 years of age;
  • Confirmed diagnosis of PNH by clinical manifestation and flow cytometry; granulocyte clone size ≥ 10%;
  • Participants who have been on a stable dose and interval of a C5 complement inhibitor (approved locally) for at least 3 months prior to the first dose of VSA012;
  • Within the 3 months prior to screening, have a documented Hb level of \< 105 g/L while on C5 complement inhibitor therapy;
  • Hb \< 105 g/L;
  • Participants are willing to receive meningococcal vaccine and pneumococcal vaccine at least 14 days prior to dosing.

Exclusion Criteria for Groups 1-4

  • History of to VSA012 or its ;
  • Use of any complement inhibitors within 3 months prior to screening
  • Use of any targeted small interfering RNA (siRNA) within 18 months prior to screening, or any antisense oligonucleotide molecule within 6 months prior to screening;
  • Supportive care for PNH does not meet the stable-dose requirements:
  • Participants have infections;
  • Laboratory tests meet the following criteria:

    1. Reticulocyte count \< 100 × 109/L;
    2. count \< 30 × 109/L;
    3. \< 0.5 × 109/L;
    4. \< 30 mL/min (calculated by the Cockcroft-Gault formula);

Exclusion Criteria for Groups 5

  • History of hypersensitivity to VSA012 or its excipients;
  • Use of any targeted small interfering RNA (siRNA) within 18 months prior to screening, or any antisense oligonucleotide molecule within 6 months prior to screening;
  • Supportive care for PNH does not meet the stable-dose requirements:
  • Participants have infections;
  • History of splenectomy;
  • Previous suspected/confirmed hereditary complement deficiency;
  • History of recurrent invasive infections with capsular bacteria, e.g., meningococcus or pneumococcus;
  • Laboratory tests meet the following criteria:

    1. Reticulocyte count \< 100 × 109/L;
    2. Platelet count \< 30 × 109/L;
    3. Neutrophil count \< 0.5 × 109/L;
    4. Creatinine clearance \< 30 mL/min (calculated by the Cockcroft-Gault formula);
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    VSA012 dose A

    Drug: VSA012

  • Experimental
    VSA012 dose B

    Drug: VSA012

  • Experimental
    VSA012 dose C

    Drug: VSA012

  • Experimental
    VSA012 dose D

    Drug: VSA012

  • Experimental
    VSA012 dose E

    Drug: VSA012

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (AEs) and/or Serious Adverse Events (SAEs)

    Time frame: up to Day 540

  2. preliminary efficacy

    Percentage change from baseline in lactate dehydrogenase (LDH) by visit Change from baseline in hemoglobin (Hb) level by visit

    Time frame: up to Day 540

Secondary outcomes

  1. Pharmacokinetics (PK) of VSA012 (First dose): Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to 48 hours post-dose

  2. PK of VSA012(First dose): Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Up to 48 hours post-dose

  3. PK of VSA012(First dose):Area under the concentration-time curve during the dosing interval (AUC 0-tau)

    Time frame: Up to 48 hours post-dose

  4. PK of VSA012 (Multiple dose):Trough concentration (C min)

    Time frame: Up to 48 hours post-dose

  5. PK of VSA012 (Multiple dose):Accumulation ratio of C max

    Time frame: Up to 48 hours post-dose

  6. PK of VSA012 (Multiple dose):AUC 0-tau

    Time frame: Up to 48 hours post-dose

  7. PK of VSA012 (Multiple dose):T max

    Time frame: Up to 48 hours post-dose

  8. PK of VSA012 (Multiple dose):C max (RacC max)

    Time frame: Up to 48 hours post-dose

  9. PK of VSA012 (Multiple dose):Accumulation ratio of AUC 0-tau (RacAUC 0-tau)

    Time frame: Up to 48 hours post-dose

  10. Pharmacodynamic (PD) profile of VSA012:Change from baseline in complement factor B (CFB) and complement bypass pathway (CAP) activities

    Time frame: up to Day 540

  11. PD of VSA012:Change from baseline in PNH clones, including number of PNH clones in erythrocytes, number of PNH clones in granulocytes, and number of PNH clones in monocytes

    Time frame: up to Day 540

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's planned 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2025
First posted
Feb 27, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Aug 31, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06848296
Lead sponsor
Bisirna Therapeutics Pte. Ltd.
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Apr 15, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
May 4, 2026

Study contacts

Bing Han
principal investigator · Peking Union Medical College Hospital
Hongyan Tong
principal investigator · Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VSA012

Start the discussion